Exploring the Overlap of MASLD and IBD: Insights from a Single-Center Experience
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110288 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ana Stemate und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology 1, Emergency University Hospital, Splaiul Independenței Street, No. 169, Sector 6, 050098 Bucharest, Romania. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Fatty Liver, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent condition worldwide, occurring both independently and, more importantly, as the most common extraintestinal complication of inflammatory bowel disease (IBD). The study primarily investigated MASLD prevalence in Crohn’s disease (CD) and ulcerative colitis (UC) to enhance prevention and early detection, especially given the recent approval of the first treatment for this condition. Secondary objectives included identifying risk factors, exploring the uric acid/high-density lipoprotein cholesterol ratio (UHRatio) as a steatosis marker and evaluating correlations between non-invasive fibrosis scores, Fibrosis-4 (FIB-4), AST-to-Platelet Ratio Index (APRI), and histological fibrosis severity. We conducted a prospective study on 58 patients diagnosed with IBD. The type of IBD was not independently associated with liver steatosis or fibrosis. Disease activity correlated significantly with hepatic steatosis in CD patients and with hepatic fibrosis in UC patients. The UHRatio proved useful in assessing steatosis prevalence, whereas FIB-4 and APRI scores did not correlate significantly with fibrosis severity. This study is, to our knowledge, the first to evaluate UHRatio as a potential predictor of MASLD in patients with IBD, expanding on previous findings reported in the general population. Our results suggest that this non-invasive biomarker, previously used to identify MASLD, may improve early prediction and could serve as a useful screening tool for MASLD in IBD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology 1, Emergency University Hospital, Splaiul Independenței Street, No. 169, Sector 6, 050098 Bucharest, Romania.
- "Carol Davila" University of Medicine and Pharmacy, Faculty of General Medicine, Dionisie Lupu Street, No. 37, Sector 2, 020021 Bucharest, Romania.
ORCID-Profile: Lucian Negreanu
Zitieren
APA
Stemate, A., Negru-Vodă, D. I., Mazurencu-Pele, A. M. P., Popescu, R. F., Spătaru, T. I., & Negreanu, L. (2025). Exploring the Overlap of MASLD and IBD: Insights from a Single-Center Experience. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110288
Vancouver
Stemate A, Negru-Vodă DI, Mazurencu-Pele AMP, Popescu RF, Spătaru TI, Negreanu L. Exploring the Overlap of MASLD and IBD: Insights from a Single-Center Experience. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110288
BibTeX
@article{Stemate2025,
author = {Stemate, Ana and Negru-Vodă, Delia-Ionela and Mazurencu-Pele, Ana Maria Patricia and Popescu, Remus-Florin and Spătaru, Teodora-Iulia and Negreanu, Lucian},
title = {Exploring the Overlap of MASLD and IBD: Insights from a Single-Center Experience},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110288}
}
EUVIMED